EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial

Roser Ayats-Vidal iD, Montserrat Bosque-García, Begoña Cordobilla iD, Oscar Asensio-De la Cruz, Miguel García-González, Susana Loureda-Pérez, Elena Fernández-López, Eva Robert-Barriocanal, Andrea Valiente-Planas, Joan Carles Domingo iD

Nutrients · 27.03.2024 · 16 (7) · 970

DOI: 10.3390/nu16070970 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 27.03.2024. Verfasst von Roser Ayats-Vidal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Parc Ta…. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bernola-Vallribera Foundation, Sant Josep 2018, Taulí Research and Innovation 2018.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A randomized, double-blind, and placebo-controlled study was conducted to assess the effect of dietary supplementation with high-rich docosahexaenoic acid (DHA) (Tridocosahexanoin-AOX® 70%) at 50 mg/kg/day in pediatric patients with cystic fibrosis (CF) as compared with placebo. The duration of supplementation was 12 months. A total of 22 patients were included, with 11 in the DHA group and 11 in the placebo group. The mean age was 11.7 years. The outcome variables were pulmonary function, exacerbations, sputum cellularity, inflammatory biomarkers in sputum and peripheral blood, and anthropometric variables. In the DHA group, there was a significant increase in FVC (p = 0.004) and FVE1 expressed in liters (p = 0.044) as compared with placebo, and a lower median number of exacerbations (1 vs. 2). Differences in sputum cellularity (predominantly neutrophilic), neutrophilic elastase, and sputum and serum concentrations of resolvin D1 (RvD1), interleukin (IL)-8 (IL-8), and tumor necrosis factor alpha (TNF-α) between the study groups were not found. Significant increases in weight and height were also observed among DHA-supplemented patients. The administration of the study product was safe and well tolerated. In summary, the use of a highly concentrated DHA supplement for 1 year as compared with placebo improved pulmonary function and reduced exacerbations in pediatric CF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansChildDocosahexaenoic AcidsAnthropometryBiomarkersDietary Supplements

Stichwörter der Autor:innen

cystic fibrosisdocosahexaenoic acidinflammatory biomarkersomega-3 fatty acidspulmonary functionrandomized controlled trial

Substanzen

Docosahexaenoic AcidsBiomarkers

Autor:innen und Institutionen

  • Pediatric Allergies, Immunology and Pneumology Unit, Pediatric Medicine Service, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Parc Taulí Hospital Universitari, Universitat Autònoma de Barcelona, Parc Tau…
  • Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, E-08028 Barcelona, Spain.
  • Physical Medicine and Rehabilitation Service, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Parc Taulí Hospital Universitari, Universitat Autònoma de Barcelona, Parc Taulí 1, E-08208 Sabadell, Spain.

ORCID-Profile: Roser Ayats-Vidal, Begoña Cordobilla, Joan Carles Domingo

Förderung

  • Bernola-Vallribera Foundation, Sant Josep 2018
  • Taulí Research and Innovation 2018

Zitieren

APA

Ayats-Vidal, R., Bosque-García, M., Cordobilla, B., Asensio-De la Cruz, O., García-González, M., Loureda-Pérez, S., Fernández-López, E., Robert-Barriocanal, E., Valiente-Planas, A., & Domingo, J. C. (2024). Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial. Nutrients, 16(7), 970. https://doi.org/10.3390/nu16070970

Vancouver

Ayats-Vidal R, Bosque-García M, Cordobilla B, Asensio-De la Cruz O, García-González M, Loureda-Pérez S, et al. Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial. Nutrients. 2024;16(7):970. doi:10.3390/nu16070970

BibTeX
@article{AyatsVidal2024,
  author = {Ayats-Vidal, Roser and Bosque-García, Montserrat and Cordobilla, Begoña and Asensio-De la Cruz, Oscar and García-González, Miguel and Loureda-Pérez, Susana and Fernández-López, Elena and Robert-Barriocanal, Eva and Valiente-Planas, Andrea and Domingo, Joan Carles},
  title = {Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial},
  journal = {Nutrients},
  year = {2024},
  volume = {16},
  number = {7},
  pages = {970},
  doi = {10.3390/nu16070970}
}
Kostenlos starten →